From Hope to Reality: Durable Overall Survival With Immune Checkpoint Inhibitors for Advanced Lung Cancer
J Clin Oncol
.
2019 Oct 1;37(28):2511-2513.
doi: 10.1200/JCO.19.01207.
Epub 2019 Jun 2.
Authors
Deepa Rangachari
1
,
Daniel B Costa
1
Affiliation
1
Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
PMID:
31154918
PMCID:
PMC6879313
DOI:
10.1200/JCO.19.01207
No abstract available
Publication types
Editorial
MeSH terms
Carcinoma, Non-Small-Cell Lung / drug therapy*
Carcinoma, Non-Small-Cell Lung / mortality
Humans
Immunotherapy / methods*
Lung Neoplasms / drug therapy*
Lung Neoplasms / mortality
Survival Analysis
Grants and funding
R37 CA218707/CA/NCI NIH HHS/United States